Latest Breaking News On - புதிதாக கண்டறியப்பட்டது - Page 8 : comparemela.com

Share this article Share this article PHILADELPHIA, Jan. 26, 2021 /PRNewswire/  Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM), today announced publication of Phase 1b clinical trial results in Clinical Cancer Research, a journal of the American Association for Cancer Research. The article Phase1b Clinical Trial of IGV-001 for patients with Newly Diagnosed Glioblastoma is available online. IGV-001 is a first-in-class personalized immunotherapy that uses the patient s own tumor cells combined with an antisense molecule to induce a potent immune response. The treatment comprises irradiated autologous glioma cells with an antisense oligodeoxynucleotide directed at the IGF-1R (Insulin-like Growth Factor type one Receptor) named IMV-001. Delivered through an implantable and removable bio-diffusion chamber, antigenic products are released and initiate both an innate and adaptive response.

Thomas jefferson universityUnited statesDavidw andrewsAnthony alfred chiurcoJohn fureyAndrewe sloanAmerican association for cancer researchNeurological institute of the university hospitalsSeidman cancer centerOncology centerImvax incClinical cancer researchGlioblastoma multiformeAmerican associationClinical trialNewly diagnosed